Dr Strnad talks to ecancertv at ASTRO 2015 about the results of a phase III trial that compared accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy versus whole breast irradiation for early breast cancer.
The primary endpoint was the 5-year local control rate and this showed that APBI was as good as whole breast irradiation. This is the first trial to prove non-inferiority of APBI in comparison to whole breast irradiation, Dr Strnad says in the interview. These potentially practice-changing data mean that it is a valid alterative treatment option to whole breast irradiation.
The results are now published in The Lancet.
Read the news story for more.